9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential.

MLA

Glaser, M., et al. “9P Small-Scale ROS1 Aberrations: Functional Impact and Therapeutic Potential.” Annals of Oncology, vol. 33, Oct. 2022, p. S1386. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.09.010.

APA

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wömpner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Büttner, R., Wolf, J., & Scheffler, M. (2022). 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Annals of Oncology, 33, S1386. https://doi.org/10.1016/j.annonc.2022.09.010

Chicago

Glaser, M., C. von Levetzow, S. Michels, L. Nogova, M. Katzenmeier, C. Wömpner, J. Schmitz, et al. 2022. “9P Small-Scale ROS1 Aberrations: Functional Impact and Therapeutic Potential.” Annals of Oncology 33 (October): S1386. doi:10.1016/j.annonc.2022.09.010.